(R)-9-Chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride | 396074-79-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (R)-9-Chloro-4-methyl-1,2,3,4-tetrahydro-pyrazino[1,2-a]indole hydrochloride
• 英文别名: (4R)-9-chloro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole;hydrochloride
• CAS: 396074-79-6
• 化学式: C₁₂H₁₃ClN₂*ClH
• 分子量: 257.163
• InChiKey: LMQQMHLHIQKHBV-DDWIOCJRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.38
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  17
• 氢给体数：
  2
• 氢受体数：
  1

文献信息

• Piperazine derivatives
  申请人：——

  公开号：US20020169163A1

  公开（公告）日：2002-11-14

  Piperazine derivatives, as well as pharmaceutically acceptable salts, solvates and esters thereof, can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, type II diabetes, obesity and sleep apnoea.

  哌嗪衍生物以及其中医药可接受的盐、溶剂合物和酯，可用于制药制剂的形式，用于治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、尿崩症、2型糖尿病、肥胖和睡眠呼吸暂停。
• Anti-obesity 1,2,3,4,10,10-a-hexahydropy razino [1,2-a] indoles
  申请人：——

  公开号：US20020035110A1

  公开（公告）日：2002-03-21

  The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a] indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

  本发明涉及1,2,3,4,10,10a,-六氢吡唑[1,2-a]吲哚衍生物以及药用可接受的盐、溶剂合物和酯，其中R1至R8具有如权利要求1中所述的意义，用于以药物制剂的形式治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠疾病、尿崩症、肥胖和睡眠呼吸暂停。
• [EN] PIPERAZINE DERIVATIVES<br/>[FR] DERIVES DE LA PIPERAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2002010169A1

  公开（公告）日：2002-02-07

  The present invention refers to chemical compounds of formula (I) as well as pharmaceutically usable salts, solvates and esters thereof, wherein R1 to R8 have the significance given in claim 1. They can be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnoea.

  本发明涉及化学式（I）的化合物，以及其可用于制药的盐，溶剂合物和酯，其中R1至R8具有权利要求1中给出的意义。它们可以用于制药制剂的形式，用于治疗或预防中枢神经系统的疾病，中枢神经系统的损伤，心血管疾病，胃肠疾病，尿崩症，肥胖症和睡眠呼吸暂停。
• Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino[1,2-a] indoles
  申请人：Bentley Mark Jonathan

  公开号：US20050239789A1

  公开（公告）日：2005-10-27

  The present invention is directed to 1,2,3,4,10,10a,-hexahydropyrazino[1,2-a]indole derivatives as well as pharmaceutically acceptable salts, solvates and esters thereof, wherein R 1 to R 8 have the significance given in claim 1 be used in the form of pharmaceutical preparations for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, obesity and sleep apnea.

  本发明涉及1,2,3,4,10,10a,-六氢吡嗪并[1,2-a]吲哚衍生物，以及其药学上可接受的盐、溶剂和酯，其中R1至R8在权利要求书中所给出的意义下使用，用于制备药物制剂，用于治疗或预防中枢神经系统疾病、中枢神经系统损伤、心血管疾病、胃肠道疾病、尿崩症、肥胖症和睡眠呼吸暂停。
• Biologically active compounds
  申请人：Quibell Martin

  公开号：US20060100431A1

  公开（公告）日：2006-05-11

  Compounds of general formula (I) wherein Z=CR 3 R 4 , where R 3 and R 4 are independently chosen from C 0-7 -alkyl P 1 =CR 5 R 6 , P 2 =O, CR 7 R 8 or NR 9 , Y=CR 10 R 11 —C(O) or CR 10 R 11 —C(S) or CR 10 R 11 —S(O) or CR 10 R 11 —SO 2 (X) 0 =.CR 16 R 17 (W) n =0 , S, C(O), S(O) or S(O) 2 — or NR 18 (V) m =C(O), C(S), S(O), S(O) 2 , S(O) 2 NH, OC(O), NHC(O), NHS(O), NHS(O) 2 , OC(O)NH, C(O)NH or CR 19 R 20 , C═N—C(O)—OR 19 or C═N═C(O)—NHR 19 , U=a stable. 5- to 7 membered monocyclic or a stable 8- to 11-membered bicyclic ring which is either saturated or unsaturated, and which includes zero to four heteroatoms and their sales, hydrates, solvates, complexes and prodruges are inhibitors of cathepsin K and other cysteine protease inhibitors and are useful as therapeutic agents, for example in osteoporosis, Paget's disease gingival diseases such as gingivitis and periodontis, hypercalaemia of malignancy, metabolic bone disease, diseases involving matrix or cartilage degradation, in particular osteoarthitis and rheumatoid arthritis and neoplastic diseases. The compounds are also useful for validating therapeutic target compounds.

  通式(I)的化合物，其中Z=CR3R4，其中R3和R4独立地选择自C0-7烷基；P1=CR5R6，P2=O，CR7R8或NR9；Y=CR10R11—C（O）或CR10R11—C（S）或CR10R11—S（O）或CR10R11—SO2（X）0=.CR16R17（W）n=0、S、C（O）、S（O）或S（O）2—或NR18（V）m=C（O）、C（S）、S（O）、S（O）2、S（O）2NH、OC（O）、NHC（O）、NHS（O）2、OC（O）NH、C（O）NH或CR19R20、C═N—C（O）—OR19或C═N═C（O）—NHR19；U=稳定的5-至7-成员单环或稳定的8-至11-成员双环，它可以是饱和或不饱和，并且可以包含零到四个杂原子，以及它们的盐、水合物、溶剂合物、配合物和前药是猫hepsin K和其他半胱氨酸蛋白酶抑制剂，可用作治疗剂，例如在骨质疏松症、帕吉特病、牙龈疾病如牙龈炎和牙周炎、恶性高钙血症、代谢性骨病、涉及基质或软骨降解的疾病，特别是骨关节炎和类风湿性关节炎和肿瘤性疾病。这些化合物也可用于验证治疗靶点化合物。